Next Article in Journal
Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells
Previous Article in Journal
Molecular Signatures of JMJD10/MINA53 in Gastric Cancer
 
 
Article

Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer

1
Exosomes Laboratory, CIC bioGUNE, 48160 Derio, Spain
2
Biodonostia, Grupo de Enfermedades Gastrointestinales, 20014 San Sebastian, Spain
3
Biodonostia, Grupo de Genética Gastrointestinal, 20014 San Sebastian, Spain
4
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 08036 Barcelona, Spain
5
OWL Metabolomics, Bizkaia Technology Park, Derio, 48160 Bizkaia, Spain
6
IKERBASQUE, Basque Foundation for Sciences, 48013 Bilbao, Spain
7
School of Biological Sciences, Monash University, Clayton VIC 3800, Australia
8
Department of Gastroenterology, Complexo Hospitalario Universitario de Ourense, Instituto de Investigación Sanitario Galicia Sur, 32005 Ourense, Spain
9
Metabolomics Platform, CIC bioGUNE, 48160 Derio, Spain
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(5), 1142; https://doi.org/10.3390/cancers12051142
Received: 16 March 2020 / Revised: 28 April 2020 / Accepted: 30 April 2020 / Published: 2 May 2020
Although colorectal cancer (CRC) is the second leading cause of death in developed countries, current diagnostic tests for early disease stages are suboptimal. We have performed a combination of UHPLC-MS metabolomics and 16S microbiome analyses on 224 feces samples in order to identify early biomarkers for both advanced adenomas (AD) and CRC. We report differences in fecal levels of cholesteryl esters and sphingolipids in CRC. We identified Fusobacterium, Parvimonas and Staphylococcus to be increased in CRC patients and Lachnospiraceae family to be reduced. We finally described Adlercreutzia to be more abundant in AD patients’ feces. Integration of metabolomics and microbiome data revealed tight interactions between bacteria and host and performed better than FOB test for CRC diagnosis. This study identifies potential early biomarkers that outperform current diagnostic tools and frame them into the stablished gut microbiota role in CRC pathogenesis. View Full-Text
Keywords: metabolomics; microbiome; omics; multiomics; omics integration; integration metabolomics; microbiome; omics; multiomics; omics integration; integration
Show Figures

Figure 1

MDPI and ACS Style

Clos-Garcia, M.; Garcia, K.; Alonso, C.; Iruarrizaga-Lejarreta, M.; D’Amato, M.; Crespo, A.; Iglesias, A.; Cubiella, J.; Bujanda, L.; Falcón-Pérez, J.M. Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer. Cancers 2020, 12, 1142. https://doi.org/10.3390/cancers12051142

AMA Style

Clos-Garcia M, Garcia K, Alonso C, Iruarrizaga-Lejarreta M, D’Amato M, Crespo A, Iglesias A, Cubiella J, Bujanda L, Falcón-Pérez JM. Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer. Cancers. 2020; 12(5):1142. https://doi.org/10.3390/cancers12051142

Chicago/Turabian Style

Clos-Garcia, Marc, Koldo Garcia, Cristina Alonso, Marta Iruarrizaga-Lejarreta, Mauro D’Amato, Anais Crespo, Agueda Iglesias, Joaquín Cubiella, Luis Bujanda, and Juan Manuel Falcón-Pérez. 2020. "Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer" Cancers 12, no. 5: 1142. https://doi.org/10.3390/cancers12051142

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop